Core Insights - Globus Medical reported revenue of $826.42 million for the quarter ended December 2025, reflecting a year-over-year increase of 25.7% and surpassing the Zacks Consensus Estimate by 4.9% [1] - The company's EPS for the quarter was $1.28, up from $0.84 in the same quarter last year, resulting in an EPS surprise of 20.76% compared to the consensus estimate of $1.06 [1] Revenue Breakdown - International revenues reached $161.1 million, exceeding the average estimate of $147.72 million by analysts, marking a 19% increase year-over-year [4] - U.S. revenues totaled $665.32 million, surpassing the average estimate of $621.92 million, with a year-over-year growth of 27.5% [4] Product Category Performance - Net sales from Enabling Technologies were $55.62 million, exceeding the average estimate of $33.7 million, representing an 18.5% increase year-over-year [4] - Net sales from Musculoskeletal Solutions amounted to $770.8 million, above the average estimate of $735.95 million, showing a year-over-year growth of 26.3% [4] Stock Performance - Shares of Globus Medical have returned +0.5% over the past month, while the Zacks S&P 500 composite has decreased by -1%, indicating potential outperformance in the near term [3]

Core Viewpoint - Globus Medical reported strong quarterly earnings of $1.28 per share, exceeding the Zacks Consensus Estimate of $1.06 per share, and showing significant growth from $0.84 per share a year ago, indicating a positive earnings surprise of +20.76% [1] Financial Performance - The company achieved revenues of $826.42 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.90% and reflecting a year-over-year increase from $657.29 million [2] - Over the last four quarters, Globus Medical has exceeded consensus EPS estimates three times and has also topped revenue estimates three times [2] Stock Performance - Since the beginning of the year, Globus Medical shares have increased by approximately 7%, contrasting with a slight decline of 0.1% in the S&P 500 [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations for it to outperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.85 on projected revenues of $734.46 million, while the estimate for the current fiscal year stands at $3.89 on revenues of $3.15 billion [7] - The trend of estimate revisions for Globus Medical has been favorable leading up to the earnings release, which may influence future stock movements [5][6] Industry Context - The Medical - Instruments industry, to which Globus Medical belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Globus Medical (NYSE:GMED) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAnna Geng - Equity Research AssociateBrian Kearns - Senior Vice President of Business Development and Investor RelationsCaitlin Cronin - VP in Equity ResearchDavid Saxon - VPKeith Hinton - Senior Vice PresidentKeith Pfeil - President and CEOKyle Kline - Chief Financial OfficerMathew Blackman - Managing DirectorMatt Miksic - Managing DirectorNamrata Marathe - Equity Research AssociateRichard Newitter - Managing ...

Globus Medical (NYSE:GMED) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAnna Geng - Equity Research AssociateBrian Kearns - Senior Vice President of Business Development and Investor RelationsCaitlin Cronin - VP in Equity ResearchDavid Saxon - VPKeith Hinton - Senior Vice PresidentKeith Pfeil - President and CEOKyle Kline - Chief Financial OfficerMathew Blackman - Managing DirectorMatt Miksic - Managing DirectorNamrata Marathe - Equity Research AssociateRichard Newitter - Managing ...

Financial Performance - For the full year 2025, Globus Medical reported revenue of $2.939 billion, representing a growth of 16.7% year-over-year, and non-GAAP earnings per share (EPS) of $3.98, up 30.8% [4][22] - In Q4 2025, revenue reached $826.4 million, a 25.7% increase compared to Q4 2024, with non-GAAP EPS of $1.28, growing 52.1% year-over-year [5][23] - The base business revenue for Q4 was $726.7 million, reflecting a 10.6% growth compared to the same quarter last year [5][25] - Adjusted EBITDA margin for Q4 was 35.7%, while the full year margin was 33.4% [6][24] Business Line Performance - The U.S. spine business grew by 10% in Q4 compared to the prior year quarter, continuing a trend of above-market growth [6][27] - Enabling Technologies revenue was $55.6 million in Q4, growing 18.5% year-over-year, driven by increased sales of EGPS systems [11][26] - The trauma business experienced approximately 27% growth in Q4, supported by the legacy trauma line and precise limb lengthening products [15][16] Market Performance - U.S. revenue in Q4 was $665.3 million, growing 27.5% year-over-year, while international revenue was $161.1 million, reflecting a 19% increase [26][27] - The international spine business faced supply chain challenges earlier in the year but showed improvement, culminating in record sales in Q4 2025 [28][80] Company Strategy and Industry Competition - The company aims to penetrate and launch new programs while fostering utilization and service excellence across its install base [14] - Globus Medical is focused on expanding its core spine business while also growing adjacent markets through innovation and product development [18][19] - The company views competition in the enabling technology space as evolving but believes its ExcelsiusGPS system remains a strong offering [12][69] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of U.S. spine growth, citing product launches and a robust sales force as key drivers [68] - The company anticipates continued margin expansion and has set a long-term goal for mid-seventies adjusted gross profit percentage [30][43] - Management acknowledged the challenges faced in international markets but remains optimistic about returning to double-digit growth rates [80] Other Important Information - The company repurchased approximately 4.3 million shares during 2025, with a remaining authorization of $390 million under its share repurchase program [37][38] - Research and development expenses for Q4 were $36.2 million, or 4.4% of sales, reflecting a decrease from the prior year [30][32] Q&A Session Summary Question: Can you bridge the growth expectations for the base business into 2026? - Management noted that 2025 was a tale of two halves, with significant growth in the latter half driven by product launches and sales force expansion [47][48] Question: How do you view market share and the strength of the spine market? - Management believes the U.S. spine business is growing above market and views the overall spine market as relatively healthy [54] Question: What changed in the enabling technology environment? - Management indicated that enabling technology performance was lumpy throughout the year, with a strong Q4 driven by closing delayed pipeline deals [59][60] Question: How sustainable is the U.S. spine growth? - Management sees the growth as durable, supported by ongoing product launches and competitive rep conversions [68][69] Question: What are the headwinds in the international market? - Management highlighted that the international business can grow 12%-15% long-term, with a focus on deepening existing markets rather than expanding into new ones [80]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ 2560 General Armistead Avenue, Audubon, PA 19403-5214 (610) 930-1800 Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact name of regis ...

AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025: Worldwide net sales were $826.4 million, an increase of 25.7%, or an increase of 24.7% on a constant currency basis.Base business, excluding Nevro, net sales were $726.7 million, an increase of 10.6%, or an increase of 9.4% on a constant currency basis.GAAP ...

Core Viewpoint - Investors in the Medical - Instruments sector may find value in either Globus Medical (GMED) or Masimo (MASI), with a closer examination needed to determine which stock is more appealing to value investors [1] Valuation Metrics - Both GMED and MASI currently hold a Zacks Rank of 2 (Buy), indicating positive revisions to their earnings estimates and improving earnings outlooks [3] - The Value category assesses undervalued companies using key metrics such as P/E ratio, P/S ratio, earnings yield, and cash flow per share [4] - GMED has a forward P/E ratio of 22.92 and a PEG ratio of 1.45, while MASI has a forward P/E of 30.36 and a PEG ratio of 1.77 [5] - GMED's P/B ratio is 2.77, contrasting with MASI's P/B of 11.61, indicating GMED is more favorably valued [6] - Based on these valuation metrics, GMED is rated with a Value grade of B, while MASI has a Value grade of D, suggesting GMED is the superior value option [6]

Core Insights - Wall Street analysts forecast that Globus Medical (GMED) will report quarterly earnings of $1.06 per share, reflecting a year-over-year increase of 26.2% [1] - Anticipated revenues for the quarter are projected to be $787.85 million, indicating a 19.9% increase compared to the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a collective reevaluation by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions to the stock, with empirical studies showing a strong relationship between earnings estimate revisions and short-term price performance [3] Key Metrics Projections - Analysts project 'Net Sales by Product Category- Enabling Technologies' to reach $33.70 million, a decrease of 28.2% from the prior-year quarter [5] - The average estimate for 'Net Sales by Product Category- Musculoskeletal Solutions' is $735.95 million, suggesting a year-over-year increase of 20.6% [5] - Estimated 'Geographic Revenues- International' are projected at $147.72 million, reflecting a 9.1% increase year over year [6] - 'Geographic Revenues- United States' are expected to reach $621.92 million, indicating a 19.2% increase from the year-ago quarter [6] Stock Performance - Globus Medical shares have experienced a decline of 4.3% in the past month, compared to a 0.8% decline in the Zacks S&P 500 composite [6] - With a Zacks Rank 2 (Buy), GMED is expected to outperform the overall market performance in the near term [6]

Industry Overview - The medical technology (MedTech) industry has evolved into a distinct global sector since the early 1990s, with a market value projected to reach $584 billion by 2025, following seven consecutive years of growth [2] - Future Market Insights Inc estimates the MedTech market at $549 billion in 2025, with expectations to grow to $853 billion by 2035, reflecting a compound annual growth rate (CAGR) of 4.5% over the next decade [3] - Key growth drivers include the integration of artificial intelligence (AI) and digital health solutions, which are enhancing patient care through improved diagnostics and efficiency [4][5] Investment Sentiment - Analysts believe that healthcare, particularly MedTech, will provide significant investment opportunities, especially as investors seek alternatives to the broader tech sector [6][7] - AI is identified as a major catalyst for growth in the MedTech sector, enhancing efficiency across the value chain from research and development to sales [7] Company Highlights ResMed Inc. (NYSE:RMD) - ResMed is recognized as a leading medical technology stock, with a hedge fund holding count of 43 and a projected stock upside of 27.97% [12] - The company reported strong Q2 fiscal 2026 results, with revenue exceeding expectations, particularly in its Masks & Accessories and Devices segments [13] - Analysts have raised price targets for ResMed, reflecting confidence in its improving profitability and strong market performance [14][15] - ResMed specializes in medical devices and digital health solutions for respiratory conditions, including CPAP machines and remote monitoring software [16] Globus Medical Inc. (NYSE:GMED) - Globus Medical is another top medical technology stock, with 46 hedge fund holdings and a stock upside of 26.12% [17] - The company received an upgrade from Needham, which set a price target of $112 following positive preliminary revenue announcements [17] - Analysts expect margin expansion and improved organic revenue growth to enhance earnings expectations for Globus [18][19] - Globus develops medical devices for musculoskeletal disorders, including implantable devices and surgical instruments [22]